CA2882743C - Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes - Google Patents

Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes Download PDF

Info

Publication number
CA2882743C
CA2882743C CA2882743A CA2882743A CA2882743C CA 2882743 C CA2882743 C CA 2882743C CA 2882743 A CA2882743 A CA 2882743A CA 2882743 A CA2882743 A CA 2882743A CA 2882743 C CA2882743 C CA 2882743C
Authority
CA
Canada
Prior art keywords
unsubstituted
substituted
compound
alkyl
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2882743A
Other languages
English (en)
French (fr)
Other versions
CA2882743A1 (en
Inventor
Wha Bin Im
Robert M. Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2882743A1 publication Critical patent/CA2882743A1/en
Application granted granted Critical
Publication of CA2882743C publication Critical patent/CA2882743C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2882743A 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes Active CA2882743C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693437P 2012-08-27 2012-08-27
US61/693,437 2012-08-27
PCT/US2013/056418 WO2014035827A1 (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (2)

Publication Number Publication Date
CA2882743A1 CA2882743A1 (en) 2014-03-06
CA2882743C true CA2882743C (en) 2021-11-30

Family

ID=49117974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882743A Active CA2882743C (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Country Status (11)

Country Link
US (2) US9024042B2 (enExample)
EP (1) EP2888239B1 (enExample)
JP (1) JP6270848B2 (enExample)
KR (2) KR20200110820A (enExample)
CN (1) CN104684904B (enExample)
AU (1) AU2013309124B2 (enExample)
CA (1) CA2882743C (enExample)
DK (1) DK2888239T3 (enExample)
ES (1) ES2711425T3 (enExample)
TR (1) TR201900863T4 (enExample)
WO (1) WO2014035827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2711425T3 (es) 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
JP6626831B2 (ja) * 2014-02-20 2019-12-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少
WO2015175544A1 (en) * 2014-05-12 2015-11-19 Allergan, Inc. Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs
WO2015179815A1 (en) * 2014-05-22 2015-11-26 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
ES2757798T3 (es) * 2014-10-02 2020-04-30 Allergan Inc Profármacos de éster de gamma-lactamas y su uso
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6353000B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE10322843A1 (de) 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
ES2549863T3 (es) * 2006-07-11 2015-11-02 Allergan, Inc. Derivados de ciclopentano como agentes antiglaucoma
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
EP2291346A2 (en) * 2008-05-15 2011-03-09 Allergan, Inc. Therapeutic substituted cyclopentanes
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2711425T3 (es) 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Also Published As

Publication number Publication date
KR102304111B1 (ko) 2021-09-23
TR201900863T4 (tr) 2019-02-21
EP2888239A1 (en) 2015-07-01
US20140057975A1 (en) 2014-02-27
KR20150046269A (ko) 2015-04-29
ES2711425T3 (es) 2019-05-03
KR20200110820A (ko) 2020-09-25
AU2013309124B2 (en) 2018-03-01
CA2882743A1 (en) 2014-03-06
AU2013309124A1 (en) 2015-03-12
EP2888239B1 (en) 2018-11-28
CN104684904B (zh) 2017-10-13
HK1211031A1 (en) 2016-05-13
JP2015528463A (ja) 2015-09-28
US9427401B2 (en) 2016-08-30
WO2014035827A1 (en) 2014-03-06
CN104684904A (zh) 2015-06-03
US20150322036A1 (en) 2015-11-12
US9024042B2 (en) 2015-05-05
JP6270848B2 (ja) 2018-01-31
DK2888239T3 (en) 2019-03-04

Similar Documents

Publication Publication Date Title
CA2882743C (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
AU2015259752B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
AU2015327817B2 (en) Ester prodrugs of gamma-lactams and their use
HK1211031B (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
HK40041854A (en) Ester prodrugs of gamma-lactams and their use
HK1229812A1 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180731

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250224